1255206-69-9Relevant articles and documents
Discovery of a potent and selective ROMK inhibitor with pharmacokinetic properties suitable for preclinical evaluation
Walsh, Shawn P.,Shahripour, Aurash,Tang, Haifeng,Teumelsan, Nardos,Frie, Jessica,Zhu, Yuping,Priest, Birgit T.,Swensen, Andrew M.,Liu, Jessica,Margulis, Michael,Visconti, Richard,Weinglass, Adam,Felix, John P.,Brochu, Richard M.,Bailey, Timothy,Thomas-Fowlkes, Brande,Alonso-Galicia, Magdalena,Zhou, Xiaoyan,Pai, Lee-Yuh,Corona, Aaron,Hampton, Caryn,Hernandez, Melba,Bentley, Ross,Chen, Jing,Shah, Kashmira,Metzger, Joseph,Forrest, Michael,Owens, Karen,Tong, Vincent,Ha, Sookhee,Roy, Sophie,Kaczorowski, Gregory J.,Yang, Lihu,Parmee, Emma,Garcia, Maria L.,Sullivan, Kathleen,Pasternak, Alexander
, p. 747 - 752 (2015)
A new subseries of ROMK inhibitors exemplified by 28 has been developed from the initial screening hit 1. The excellent selectivity for ROMK inhibition over related ion channels and pharmacokinetic properties across preclinical species support further pre
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
, (2017/07/31)
The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylax
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
, (2016/08/23)
The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
